Insulet Co. (NASDAQ:PODD) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Insulet Co. (NASDAQ:PODDGet Free Report) have received an average rating of “Moderate Buy” from the sixteen analysts that are presently covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation and thirteen have issued a buy recommendation on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $259.33.

A number of research analysts recently issued reports on PODD shares. SVB Leerink started coverage on Insulet in a report on Monday, October 16th. They set an “outperform” rating and a $184.00 target price on the stock. Morgan Stanley raised Insulet from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $185.00 to $234.00 in a report on Monday, December 4th. Leerink Partnrs reiterated an “outperform” rating on shares of Insulet in a research report on Monday, October 16th. Robert W. Baird upgraded Insulet from a “neutral” rating to an “outperform” rating and increased their price target for the company from $180.00 to $238.00 in a research report on Thursday, December 21st. Finally, Piper Sandler decreased their price target on Insulet from $325.00 to $250.00 and set an “overweight” rating for the company in a research report on Friday, November 3rd.

View Our Latest Stock Analysis on PODD

Insiders Place Their Bets

In other news, Director Shacey Petrovic sold 20,000 shares of Insulet stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $164.33, for a total value of $3,286,600.00. Following the completion of the transaction, the director now directly owns 2,567 shares of the company’s stock, valued at approximately $421,835.11. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.90% of the company’s stock.

Hedge Funds Weigh In On Insulet

A number of hedge funds and other institutional investors have recently modified their holdings of PODD. HighTower Advisors LLC grew its holdings in shares of Insulet by 1.4% in the first quarter. HighTower Advisors LLC now owns 2,968 shares of the medical instruments supplier’s stock valued at $948,000 after acquiring an additional 41 shares in the last quarter. Moneta Group Investment Advisors LLC grew its holdings in shares of Insulet by 7.7% in the second quarter. Moneta Group Investment Advisors LLC now owns 743 shares of the medical instruments supplier’s stock valued at $214,000 after acquiring an additional 53 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd grew its holdings in Insulet by 0.9% during the second quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 6,064 shares of the medical instruments supplier’s stock valued at $1,748,000 after purchasing an additional 55 shares during the period. Banco Bilbao Vizcaya Argentaria S.A. lifted its position in shares of Insulet by 2.9% during the second quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 1,963 shares of the medical instruments supplier’s stock worth $566,000 after acquiring an additional 55 shares in the last quarter. Finally, Consolidated Portfolio Review Corp lifted its position in shares of Insulet by 1.6% during the fourth quarter. Consolidated Portfolio Review Corp now owns 3,713 shares of the medical instruments supplier’s stock worth $806,000 after acquiring an additional 57 shares in the last quarter.

Insulet Price Performance

Shares of NASDAQ PODD opened at $194.02 on Monday. The firm has a market capitalization of $13.55 billion, a PE ratio of 113.46, a P/E/G ratio of 2.19 and a beta of 1.05. The company has a debt-to-equity ratio of 2.26, a current ratio of 3.26 and a quick ratio of 2.35. Insulet has a 1-year low of $125.82 and a 1-year high of $335.91. The business’s fifty day moving average price is $202.12 and its two-hundred day moving average price is $190.98.

Insulet (NASDAQ:PODDGet Free Report) last released its earnings results on Thursday, November 2nd. The medical instruments supplier reported $0.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.40 by $0.31. The firm had revenue of $432.70 million for the quarter, compared to analyst estimates of $413.82 million. Insulet had a return on equity of 23.98% and a net margin of 7.71%. On average, research analysts expect that Insulet will post 1.97 EPS for the current year.

Insulet Company Profile

(Get Free Report

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager.

Recommended Stories

Analyst Recommendations for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.